| 刘德忠,李槐,曾辉英,李忱瑞,史仲华,周纯武.经动脉灌注健择治疗中晚期胰腺癌临床疗效初步观察[J].中国医学影像技术,2000,16(11):928~930 |
| 经动脉灌注健择治疗中晚期胰腺癌临床疗效初步观察 |
| Transarterial Infusion Chemotherapy of Gemcitabine for the Management of Advanced Pancreatic Carcinoma |
| 投稿时间：2000-07-26 |
| DOI： |
| 中文关键词: 胰腺癌 健择 动脉灌注化疗 临床受益反应 |
| 英文关键词:Pancreatic carcinoma Gemcitabine Transarterial chemotherapy Clinical benefit response |
| 基金项目:本课题为国家“九五”攻关资助项目( 962907203205) 。 |
|
| 摘要点击次数: 1949 |
| 全文下载次数: 30 |
| 中文摘要: |
| 目的回顾性分析经动脉灌注健择(盐酸吉西他滨) 治疗中晚期胰腺癌临床疗效。方法13 例中晚期胰
腺癌患者接受动脉灌注健择治疗。治疗后观察肿瘤改善情况及临床受益反应(CBR) 。结果PR 1 例(7.7 %) ,NC 3
例(23 %) ,SD 3 例(23 %) ,6 例无法评价。Kaplan-Meier 法计算6 个月累积生存率为46188 % ,频数分布法计算中位
生存期为5.5 个月,中位进展期为2.69 个月。临床受益率为30.76 %(与文献相比P < 0.001) 。结论无论对于初
治或化疗无效的病人,动脉灌注健择均显示出良好的临床受益反应;并能有效延长病人的生存时间。 |
| 英文摘要: |
| Purpose The effectiveness of transarterial infusion chemotherapy of gemcitabine for management of advanced
pancreatic carcinoma was retrospectively analyzed. Methods Gemcitabine was administered to 13 patients with advanced
pancreatic carcinoma via an interarterial catheter. Karnofsky performance score was ( KPS) > 50. Results Of 1 patient
(7.7 %) obtained partial response (PR) , and 3 patients (23 %) achieved no change of their disease. Probability for 6 month
cumulative survival rate was 46.88 % ,median survival period was 5.5 months. No serious side effects were observed. Clinical
benefit response (CBR) was 30.76 %. The median time to progression was 2.69 months. Conclusion Transarterial infusion of gemcitabine appears well tolerated and promising CBR in patients with advanced pancreatic carcinoma. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
